← Back to Search
C-jun Oncogene Expression In Transitional Cell Carcinoma Of The Urinary Bladder.
D. Tiniakos, K. Mellon, J. Anderson, M. Robinson, D. Neal, C. Horne
Published 1994 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
OBJECTIVE To investigate c-jun oncoprotein expression in transitional cell carcinomas (TCCs) of the urinary bladder and to determine its relationship to tumour grade and stage, and to the expression of epidermal growth factor receptor (EGFR), c-erbB-2 and p53 oncoproteins. MATERIALS AND METHODS The expression of c-jun was studied using immunohistochemistry in a series of 48 TCCs of known EGFR, c-erbB-2 and p53 status. RESULTS Forty-four of 48 (92%) tumours showed c-jun specific nuclear immunoreactivity of variable intensity. The intensity of c-jun immunostaining was significantly related to tumour stage (P = 0.009) and EGFR status (P = 0.01). There was no correlation between c-jun oncoprotein expression and c-erbB-2 or p53 immunoreactivity. c-jun expression was not related to clinical outcome in terms of patient survival or rate of tumour recurrence. CONCLUSION The c-jun oncoprotein is expressed in the majority of TCCs of the urinary bladder. There is a positive association between intense c-jun immunoreactivity and muscle invasive growth, and EGFR positivity in TCCs.
This paper references
Studies of c‐jun oncogene expression in human breast using a new monoclonal antibody, NCL‐DK4
D. Tiniakos (1994)
Molecular biology of urological tumours.
P. Russell (1990)
Overexpression of c-jun, junB, or junD affects cell growth differently.
M. Castellazzi (1991)
Epidermal growth factor receptor and bladder cancer: a review.
D. Neal (1992)
Ha-ras oncogenes are activated by somatic alterations in human urinary tract tumours
J. Fujita (1984)
Evolution of phosphofructokinase—gene duplication and creation of new effector sites
R. Poorman (1984)
Oncogenes and bladder cancer.
P. Malone (1985)
Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder.
C. Wright (1991)
Expression of proto-oncogene c-jun during differentiation of B-chronic lymphocytic leukemia.
S. Gignac (1990)
Expression of c-jun, jun-B, and c-fos proto-oncogenes in human primary melanocytes and metastatic melanomas.
D. Yamanishi (1991)
Transformation suppressor activity of a Jun transcription factor lacking its activation domain
A. Lloyd (1991)
Correlation of c-fos/c-jun expression with histiocytic differentiation in Hodgkin's Reed-Sternberg cells. Examination in HDLM-1 subclones with spontaneous differentiation.
S. Hsu (1992)
Induction of proto-oncogene JUN/AP-1 by serum and TPA
W. Lamph (1988)
Epidermal growth factor stimulates transcription of the c-jun proto-oncogene in rat fibroblasts
B. Quantin (1988)
This paper is referenced by
Biología molecular en el cáncer vesical
J. Kindelan (2000)
C-Jun expression in lichen planus, psoriasis, and cutaneous squamous cell carcinoma, an immunohistochemical study
A. Abdou (2018)
Value of glutathione S-transferase pi and the oncogene products c-Jun, c-Fos, c-H-Ras, and c-Myc as a prognostic indicator in endometrial carcinomas.
Y. Yokoyama (1998)
Cigarette smoke extract-induced proliferation of normal human urothelial cells via the MAPK/AP-1 pathway.
H. Geng (2017)
Prognostic significance of glutathione S-transferase π and c-Jun in epithelial ovarian cancers
Y. Yokoyama (2007)
Molecular Biology and Bladder Cancer
J. Lunec (1994)
Promotion effects of acetoaceto-o-toluidide on N-butyl-N-(4-hydroxybutyl)nitrosamine-induced bladder carcinogenesis in rats
Nao Yukimatsu (2019)
Molecular pathogenesis and diagnostics of bladder cancer.
A. P. Mitra (2009)
Prognostic role of c-Jun activation in patients with areca quid chewing-related oral squamous cell carcinomas in Taiwan.
Ru-Cheng Kuo (2006)
Expression of urokinase plasminogen activator and receptor in conjunction with the ets family and AP-1 complex transcription factors in high grade prostate cancers.
D. Gavrilov (2001)
Expression of c-jun oncogene in hyperplastic and carcinomatous human prostate.
D. Tiniakos (2006)
Biomarkers in bladder cancer: translational and clinical implications.
L. Cheng (2014)
c-Jun is involved in interstitial cystitis antiproliferative factor (APF)-induced growth inhibition of human bladder cancer T24 cells.
Z. Li (2013)
Correlation between p53 mutations and HPV in bilharzial bladder cancer.
H. Khaled (2003)
Strategies for molecular expression profiling in bladder cancer
A. P. Mitra (2009)
Quantitative relationship between arsenic exposure and AP-1 activity in mouse urinary bladder epithelium.
P. Simeonova (2001)
Proposed Mechanisms of Arsenic Toxicity Carcinogenesis
M. Luster (2001)
The Expression of Oncoproteins in Transitional Cell Carcinoma: Its Correlation with Pathological Behavior, Cell Cycle and Drug Resistance
D. Yu (2002)
Arsenic mediates cell proliferation and gene expression in the bladder epithelium: association with activating protein-1 transactivation.
P. Simeonova (2000)
Overexpressed DNA Polymerase Iota Regulated by JNK/c-Jun Contributes to Hypermutagenesis in Bladder Cancer
F. Yuan (2013)
Expression profiling for bladder cancer: strategies to uncover prognostic factors
G. Bartsch (2010)
L. Cheng (2012)
The role of c-Jun in the AP-1 activation induced by naturally occurring isothiocyanates.
J. Li (2005)
c-Jun phosphorylation by the human vaccinia-related kinase 1 (VRK1) and its cooperation with the N-terminal kinase of c-Jun (JNK)
A. Sevilla (2004)
Arsenic and urinary bladder cell proliferation.
M. Luster (2004)
Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urothelium in vivo
F. L. Egerod (2005)
44 – Cancer of the Bladder
M. Zelefsky (2010)
Generation of a concise gene panel for outcome prediction in urinary bladder cancer.
A. P. Mitra (2009)
Risk Factors Predictive of Para‐Aortic Lymph Node Metastasis in Endometrial Carcinomas *
Y. Yokoyama (1997)
Current concepts in biomarker technology for bladder cancers.
M. Burchardt (2000)
Significance of Multi‐Drug‐Resistant Proteins in Predicting Chemotherapy Response and Prognosis in Epithelial Ovarian Cancer *
Y. Yokoyama (1999)
Urine based markers of urological malignancy.
B. Konety (2001)See more